Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ABVC NASDAQ:BMEA NASDAQ:CGTX NASDAQ:COYA On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeABVCABVC BioPharma$1.08-0.3%$1.21$0.88▼$5.48$27.40M0.4277,286 shs6,562 shsBMEABiomea Fusion$1.36-4.9%$1.55$0.87▼$3.08$98.69M-0.321.39 million shs640,858 shsCGTXCognition Therapeutics$1.14-5.4%$1.07$0.22▼$3.83$101.58M1.811.04 million shs333,630 shsCOYACoya Therapeutics$5.15-2.2%$4.38$3.71▼$7.75$120.80M0.55188,379 shs39,382 shsMetaverse Stocks And Why You Can't Ignore ThemThinking about investing in Meta, Roblox, or Unity? Click the link to learn what streetwise investors need to know about the metaverse and public markets before making an investment.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceABVCABVC BioPharma+0.93%-1.82%-20.59%-35.33%-26.03%BMEABiomea Fusion-3.38%-12.27%-26.67%+14.40%-2.05%CGTXCognition Therapeutics0.00%+3.45%+23.03%+7.14%+259.82%COYACoya Therapeutics+15.86%+25.24%+17.94%+11.68%-7.56%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeABVCABVC BioPharma$1.08-0.3%$1.21$0.88▼$5.48$27.40M0.4277,286 shs6,562 shsBMEABiomea Fusion$1.36-4.9%$1.55$0.87▼$3.08$98.69M-0.321.39 million shs640,858 shsCGTXCognition Therapeutics$1.14-5.4%$1.07$0.22▼$3.83$101.58M1.811.04 million shs333,630 shsCOYACoya Therapeutics$5.15-2.2%$4.38$3.71▼$7.75$120.80M0.55188,379 shs39,382 shsMetaverse Stocks And Why You Can't Ignore ThemThinking about investing in Meta, Roblox, or Unity? Click the link to learn what streetwise investors need to know about the metaverse and public markets before making an investment.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceABVCABVC BioPharma+0.93%-1.82%-20.59%-35.33%-26.03%BMEABiomea Fusion-3.38%-12.27%-26.67%+14.40%-2.05%CGTXCognition Therapeutics0.00%+3.45%+23.03%+7.14%+259.82%COYACoya Therapeutics+15.86%+25.24%+17.94%+11.68%-7.56%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceABVCABVC BioPharma 1.00SellN/AN/ABMEABiomea Fusion 2.89Moderate Buy$8.29509.24% UpsideCGTXCognition Therapeutics 2.50Moderate Buy$3.33193.69% UpsideCOYACoya Therapeutics 2.67Moderate Buy$16.00210.92% UpsideCurrent Analyst Ratings BreakdownLatest ABVC, CGTX, BMEA, and COYA Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/5/2026BMEABiomea Fusion CitigroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageBuy ➝ Outperform5/5/2026BMEABiomea Fusion Citizens JmpSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageMarket Outperform$9.005/1/2026ABVCABVC BioPharma Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeSell (D-) ➝ Sell (E+)4/28/2026BMEABiomea Fusion D. Boral CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$12.004/20/2026BMEABiomea Fusion Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (E+)4/20/2026COYACoya Therapeutics Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)4/10/2026COYACoya Therapeutics D. Boral CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$15.004/8/2026BMEABiomea Fusion D. Boral CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$12.003/27/2026CGTXCognition Therapeutics Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)3/27/2026BMEABiomea Fusion CitigroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$6.00 ➝ $7.003/27/2026CGTXCognition Therapeutics Chardan CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$4.00(Data available from 5/15/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookABVCABVC BioPharma$510K53.72N/AN/A$0.52 per share2.07BMEABiomea FusionN/AN/AN/AN/A$0.26 per shareN/ACGTXCognition TherapeuticsN/AN/AN/AN/A$0.33 per shareN/ACOYACoya Therapeutics$7.95M15.19N/AN/A$2.09 per share2.46Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateABVCABVC BioPharma-$7.91M-$0.40N/AN/AN/AN/A-65.11%-40.13%5/19/2026 (Estimated)BMEABiomea Fusion-$61.80M-$0.68N/AN/AN/AN/A-265.37%-103.96%N/ACGTXCognition Therapeutics-$23.49M-$0.24N/AN/AN/AN/A-72.68%-53.07%N/ACOYACoya Therapeutics-$21.23M-$1.27N/AN/AN/A-266.10%-55.86%-48.86%N/ALatest ABVC, CGTX, BMEA, and COYA EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/12/2026Q1 2026COYACoya Therapeutics-$0.39-$0.32+$0.07-$0.32$0.15 million$0.25 million5/11/2026Q1 2026BMEABiomea Fusion-$0.24-$0.17+$0.07-$0.17N/AN/A5/7/2026Q1 2026CGTXCognition Therapeutics-$0.06-$0.05+$0.01-$0.05$4.40 millionN/A3/26/2026Q4 2025CGTXCognition Therapeutics-$0.06-$0.02+$0.04-$0.02N/AN/A3/16/2026Q4 2025COYACoya Therapeutics-$0.08-$0.34-$0.26-$0.34$1.93 million$3.96 million3/3/2026Q4 2025ABVCABVC BioPharmaN/A-$0.11N/A-$0.11N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthABVCABVC BioPharmaN/AN/AN/AN/AN/ABMEABiomea FusionN/AN/AN/AN/AN/ACGTXCognition TherapeuticsN/AN/AN/AN/AN/ACOYACoya TherapeuticsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioABVCABVC BioPharmaN/A0.410.41BMEABiomea FusionN/A4.985.23CGTXCognition TherapeuticsN/A5.923.45COYACoya TherapeuticsN/A15.028.50Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipABVCABVC BioPharma11.38%BMEABiomea Fusion96.72%CGTXCognition Therapeutics43.35%COYACoya Therapeutics39.75%Insider OwnershipCompanyInsider OwnershipABVCABVC BioPharma19.00%BMEABiomea Fusion18.42%CGTXCognition Therapeutics14.40%COYACoya Therapeutics12.00%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableABVCABVC BioPharma3025.44 million20.61 millionNot OptionableBMEABiomea Fusion5072.30 million58.98 millionOptionableCGTXCognition Therapeutics2089.50 million76.61 millionNot OptionableCOYACoya Therapeutics623.46 million20.64 millionNot OptionableABVC, CGTX, BMEA, and COYA HeadlinesRecent News About These CompaniesCoya Therapeutics secures FDA fast track status for COYA 302May 14 at 11:18 PM | finance.yahoo.comFDA puts injection therapy COYA 302 on fast track for treating ALSMay 13 at 9:35 AM | alsnewstoday.comACoya Therapeutics, Inc. (NASDAQ:COYA) Receives Consensus Recommendation of "Moderate Buy" from AnalystsMay 13 at 4:17 AM | americanbankingnews.comCoya Therapeutics Inc COYAMay 12 at 6:55 PM | morningstar.comMCoya Therapeutics Has Been Granted U.S. FDA Fast Track Designation for COYA 302 for the Treatment of Amyotrophic Lateral Sclerosis (ALS)May 12 at 6:55 PM | pharmiweb.comPCoya Therapeutics Establishes $30 Million ATM Equity ProgramMay 12 at 10:10 AM | tipranks.comCoya Therapeutics Updates Q1 Results, COYA 302 ProgressMay 12 at 8:51 AM | tipranks.comCoya Therapeutics Reports First Quarter 2026 Financial Results and Provides a Corporate UpdateMay 12 at 7:35 AM | businesswire.comCoya Therapeutics (COYA) Projected to Post Quarterly Earnings on TuesdayMay 10, 2026 | americanbankingnews.comCoya Therapeutics (COYA) Expected to Announce Earnings on TuesdayMay 5, 2026 | marketbeat.comCoya Therapeutics, Inc. (NASDAQ:COYA) Receives Consensus Rating of "Moderate Buy" from BrokeragesApril 18, 2026 | marketbeat.comCoya Therapeutics (NASDAQ:COYA) Upgraded to "Hold" at Wall Street ZenApril 18, 2026 | marketbeat.comCoya Therapeutics Announces Publication Demonstrating Correlation Between Longitudinal Biomarker Data and Clinical Outcomes Supporting the Mechanistic Rationale for COYA 302 in ...April 10, 2026 | finance.yahoo.comCoya Therapeutics Announces Planned Board Transition and Appointment of Mark H. Pavao as Independent DirectorApril 2, 2026 | pharmiweb.comPCoya Therapeutics Announces Leadership Changes and New DirectorApril 2, 2026 | tipranks.comCoya Therapeutics: Advancing Treg-Focused Pipeline with Near-Term Catalysts in ALS and FTD Supporting Buy RatingMarch 23, 2026 | tipranks.comCoya Therapeutics Announces Publication Demonstrating Regulatory T-Cell Dysfunction and Systemic Inflammation in Frontotemporal Dementia, Supporting Mechanistic Rationale for ...March 18, 2026 | finance.yahoo.comCoya Therapeutics Provides a Corporate Update and Reports Fiscal 2025 Financial ResultsMarch 16, 2026 | pharmiweb.comPPlus Therapeutics (PSTV) Gets a Buy from Lake StreetMarch 6, 2026 | theglobeandmail.comCoya Therapeutics, Inc. (COYA) Upgraded to Buy: What Does It Mean for the Stock?February 25, 2026 | zacks.comAnalysts Offer Insights on Healthcare Companies: Brookdale Senior Living (BKD) and Coya Therapeutics, Inc. (COYA)February 21, 2026 | theglobeandmail.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeABVC, CGTX, BMEA, and COYA Company DescriptionsABVC BioPharma NASDAQ:ABVC$1.08 0.00 (-0.28%) As of 10:50 AM Eastern This is a fair market value price provided by Massive. Learn more.ABVC BioPharma, Inc., a clinical stage biopharmaceutical company, develops drugs and medical devices to fulfill unmet medical needs in the United States. The company is developing ABV-1501, which is in Phase II clinical trials a combination therapy for triple negative breast cancer; ABV-1504 has completed Phase II clinical trials for major depressive disorders; ABV-1505, which is in Phase II clinical trials for adult attention deficit hyperactivity disorder; ABV-1703, which is in Phase II clinical trials for the treatment of metastatic pancreatic cancer; ABV-1702, which is in Phase II clinical trials to treat myelodysplastic syndromes; and ABV-1601 that is in Phase I/II clinical trials for treating depression in cancer patients. It is also developing ABV-1701 Vitargus that is in Phase II clinical trials for the treatment of retinal detachment or vitreous hemorrhage; and ABV-1519, which is in Phase I/II clinical trials for the treatment of non-small cell lung cancer. ABVC BioPharma, Inc. has a co-development agreement with Rgene Corporation; and collaboration agreements with BioHopeKing Corporation and BioFirst Corporation. The company is based in Fremont, California. ABVC BioPharma, Inc. operates as a subsidiary of YuanGene Corporation.Biomea Fusion NASDAQ:BMEA$1.36 -0.07 (-4.90%) As of 10:52 AM Eastern This is a fair market value price provided by Massive. Learn more.Biomea Fusion, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of covalent small molecule drugs to treat patients with genetically defined cancers and metabolic diseases. Its lead product candidate is BMF-219, a covalent inhibitor of menin for treating patients with liquid and solid tumors and type 2 diabetes. The company was incorporated in 2017 and is headquartered in Redwood City, California.Cognition Therapeutics NASDAQ:CGTX$1.14 -0.07 (-5.42%) As of 10:53 AM Eastern This is a fair market value price provided by Massive. Learn more.Cognition Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of small molecule therapeutics targeting age-related degenerative diseases and disorders of the central nervous system and retina. Its lead product candidate is CT1812, an orally delivered molecule modulator designed to penetrate the blood-brain barrier and bind selectively to the S2R complex, which is in Phase 2 clinical trial for the treatment of Alzheimer's disease, as well as geographic atrophy secondary to dry age-related macular degeneration and synucleinopathies, such as dementia with Lewy bodies. The company was incorporated in 2007 and is headquartered in Purchase, New York.Coya Therapeutics NASDAQ:COYA$5.15 -0.11 (-2.17%) As of 10:53 AM Eastern This is a fair market value price provided by Massive. Learn more.Coya Therapeutics, Inc., a clinical-stage biotechnology company, engages in the development of proprietary medicinal products to modulate the function of regulatory T cells (Tregs). The company's product candidate pipeline is based on therapeutic modalities, such as Treg-enhancing biologics, Treg-derived exosomes, and autologous Treg cell therapy. It is developing COYA 101, an autologous regulatory T-cell product candidate that has completed Phase 2a clinical trial for use in the treatment of Amyotrophic Lateral Sclerosis. The company's product candidates in IND-enabling studies include COYA 301, a low-dose interleukin 2 Treg-enhancing biologic, which is in Phase 2 clinical trial for use in the treatment of Frontotemporal Dementia; and COYA 302, a biologic combination for subcutaneous administration intended to enhance Treg function while depleting T effector function and activated macrophages for use in the treatment of neurodegenerative and autoimmune diseases. It is also developing COYA 201, an antigen directed Treg-derived exosome product candidate that is in preclinical stage for use in the treatment of neurodegenerative, autoimmune, and metabolic diseases; and COYA 206, an antigen directed Treg-derived exosome product candidate, which is in discovery stage. The company has a collaboration with Dr. Reddy's Laboratories SA for the development and commercialization of COYA 302, an investigational combination therapy for treatment of amyotrophic lateral sclerosis. The company was incorporated in 2020 and is headquartered in Houston, Texas. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas YETI Rallies After Earnings Beat and Raised Outlook Aeluma's Post-Earnings Dip Creates a Buying Opportunity Cisco’s Vertical Rally May Still Be in the Early Innings Be Ready: 3 Upcoming Catalysts Could Drive Oracle to Record Highs McDonald's Is the Cheapest It’s Been in Years—Does That Make It a Buy? Dividend Growth or High Yield: The Income Investor's Bet Karman: Defense Darling's Outlook Strengthens After 40% Drop Nebius Upside Expands as AI Feedback Loop Intensifies Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
